Uploaded September 2022 | Updated September 2026, 3 days ago
In this insightful session from the EASD 2022 Annual Meeting, experts Prof. Jerry Greenfield and Ass. Prof. Husam Ghanim discuss the promising potential of adjunct therapies for type 1 diabetes. Learn about the benefits of GLP-1 receptor agonists and SGLT2 inhibitors in managing weight, metabolic control, cardiovascular risk, and more. These therapies, often used for type 2 diabetes, are showing promising results in type 1 diabetes treatment. The discussion covers their impact on A1C, insulin secretion, and overall quality of life for patients. Discover how these therapies are reshaping diabetes care!
Don’t miss out on this critical conversation on the future of type 1 diabetes treatment.
#easd2022 #T1D #diabetes #adjuncttherapies #metabolichealth
In this insightful session from the EASD 2022 Annual Meeting, experts Prof. Jerry Greenfield and Ass. Prof. Husam Ghanim discuss the promising potential of adjunct therapies for type 1 diabetes. Learn about the benefits of GLP-1 receptor agonists and SGLT2 inhibitors in managing weight, metabolic control, cardiovascular risk, and more. These therapies, often used for type 2 diabetes, are showing promising results in type 1 diabetes treatment. The discussion covers their impact on A1C, insulin secretion, and overall quality of life for patients. Discover how these therapies are reshaping diabetes care!
Don’t miss out on this critical conversation on the future of type 1 diabetes treatment.
#easd2022 #T1D #diabetes #adjuncttherapies #metabolichealth
